Cytovation

Cytovation AS operates as a biotech company. The Company specializes in dermatological diseases. Cytovation focuses on developing a treatment for benign skin tumours, as well as conducting research and development services.In June 2023, Cytovation ASA closed its $8 million (NOK 85 million) Series A extension financing round.In January 2022, Cytovation AS announced the successful closing of its Series A financing round, raising a total of NOK 180 million.In June 2017, the company raised NOK 20 million (US $2.37 million) through private funding